Oil Industry. Subject to their offering adequate potential for economically viable marketing of LPG, the remaining 9 towns will be taken up for LPG facility from time to time.

Drugs Under The National Health Programme

*392. SHRI RAFIQUE ALAM:
SHRI RAJNI RANJAN SAHU:

Will the Minister of INDUSTRY be pleased to state:

(a) whether the Ministry of Health and family Welfare have recommended to his Ministry the names of drugs required for control of diseases under the National Health Programme; if so, what are the names of those drugs and what action has since been taken in regard thereto;

(b) whether recommendations regarding category II drugs have also been received from the Kelkar Committee; and

(c) what are the names of the drugs indicating the basis of and criteria adopted for identification of each drug?

THE MINISTER OF INDUSTRY (SHRI J. VENGAL RAO): (a) Yes, Sir. The Ministry of Health and Family Welfare have given a list of names of drugs required for control of diseases under the National Health Programme. The list which would form Category I drugs to be included in the new Drugs (Prices Control) Order is under examination.

(b) and (c) The Kelkar Committee has submitted its report regarding Category II drugs. The recommendations of the Committee are under examination.

Performance of BHEL Generating Sets

*393. SHRI ATAL BIHARI VAJPAYEE:
SHRI KAILASH PATI MISHRA:

Will the Minister of INDUSTRY be pleased to state:

(a) whether Government have made any critical study of the overall performance including maintenance, operational and efficiency problems of BHEL generating sets and other products as compared with imported ones; if so, what are the details thereof;

(b) what is the existing dependency on foreign collaborations in BHEL products and the outgo in the form of royalties and other payments per annum in respect thereof; and

(c) what is the number of generating sets exclusively produced and delivered by BHEL by 1986 and how many of them have been commissioned, indicating their capacity utilisation and their rated capacity?

THE MINISTER OF INDUSTRY (SHRI J. VENGAL RAO): (a) The performance of power generating sets, whether indigenous or imported, depends besides the quality of the equipment, on a number of factors like the quality of inputs, operating skill, proper maintenance practices, etc. Keeping all factors in view, the Central Electricity Authority sets generation targets for various power stations. BHEL sets have exceeded the generation targets set by CEA during 1985-86 and 1986-87, and the first quarter of 1987-88.

(b) BHEL has successfully assimilated technology through foreign collaborations and has developed capability to execute on a turnkey basis thermal and hydro projects and to supply a wide range of equipment in power, industry and transport sectors. However, they enter into foreign collaborations on a selective basis to

meet customer preferences and market needs. The expenditure in 1985-86 on account of royalty, know-how, etc., was Rs. 10.27 crores.

(c) The number of generating sets supplied and commissioned by BHEL at the end of 1986 is as follows:

	Thermal	Hydro
Set supplied	167	211
Sets commissioned	140	128

The average plant load factor of thermal sets supplied by BHEL was 53.5 per cent in 1986-87 as against the all-India average of 53.2 per cent.

Production of Terbutaline Sulphate

*394. SHRI RAJNI RANJAN SAHU: Will the Minister of INDUSTRY be pleased to state:

(a) whether it is a fact that Terbutaline Sulphate is being produced in the country from intermediate as well as from basic stages;

(b) what are the names of the companies which are producing this drug from intermediate/penultimate Stages;

(c) what is the name of intermediate of penultimate drug being used for the production of Terbutaline Sulphate;

(d) whether Government have taken any steps to encourage production from basic stage of this drug; and

(e) if so, what are the details thereof?

THE MINISTER OF INDUSTRY (SHRI J. VENGAL RAO): (a) to (e) Industrial approvals have been granted to various companies for manufacture of Terbutaline Sulphate from intermediates, for a limited period and thereafter from basic stage. Details are given in the (enclosed Statement See below). The new measures also aim at encouraging Basic Stage production.

Statement

Sl.No.	Name of the Co.	Approved Stage of Manufacture
1	M/s. Astra-IDL	From 3, 5 Di-Benzyloxy Acetophenone and 30 Butyl Benzylamine for a period of five years from the date of implementation of licence or indigenously available. whichever is earlier. From the Sixth year onwards the party will manufacture these intermediates themselves the import of which shall be governed by the import policy in vogue at that time.
2	M/s. S.G. Chemicals	From Company's own production of 3, 5 Dihydroxy Benzoic Acid (Baisc stage).
3	M/s. Standard Organics	From 3, 5 Dihydroxy Acetophenone for a period of three years. Thereafter from Dihydroxy Benzoic Acid.
4	M/s. CIPLA	From 3, 5 Libenzyloxy Acetophenone for a period of three years. Thereafter from Dihydroxy Benzoic Acid.
5	M/s. Uni-Chem	As in CIPLA
6	M/s. Biological Evans	Based on 3, 5 Di-benzyloxy Acetophenone.
7	Ms/. Fairdeal	As in CIPLA
8	M/s. Dileep Kashmiri.	As in CIPLA